Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics Announces Poster Presentation of C-IBS Candidate Therapy Data at Digestive Disease Week® 2015

PR Newswire February 17, 2015

Synthetic Biologics Announces Positive Topline Results from Phase 1b Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

PR Newswire February 10, 2015

Synthetic Biologics to Present at the 2015 BIO CEO & Investor Conference

PR Newswire February 3, 2015

Synthetic Biologics to Present at the Biotech Showcase(TM) 2015 Conference

PR Newswire January 7, 2015

Synthetic Biologics Announces First Patient Dosed in Phase 1b Clinical Trial of SYN-004 for the Prevention of C. difficile Infection

PR Newswire December 30, 2014

Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection

PR Newswire December 22, 2014

Synthetic Biologics Announces First Patient Dosed in Phase 1a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection

PR Newswire December 2, 2014

Synthetic Biologics Safe-to-Proceed Under IND to Initiate Clinical Trials of SYN-004 for the Prevention C. difficile Infection

PR Newswire November 24, 2014

Synthetic Biologics Reports Third Quarter 2014 Financial Results and Operational Highlights

PR Newswire November 14, 2014

Synthetic Biologics to Report Third Quarter 2014 Financial Results

PR Newswire November 6, 2014

Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program

PR Newswire October 22, 2014

Synthetic Biologics Appoints Prominent Gastrointestinal (GI) Key Opinion Leaders to Irritable Bowel Syndrome (IBS) Clinical Advisory Board

PR Newswire October 15, 2014

Synthetic Biologics to Raise $20.7 Million in Registered Direct Offering

PR Newswire October 10, 2014

Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day

PR Newswire September 16, 2014

Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)

PR Newswire September 12, 2014

Synthetic Biologics to Host Phase II Trimesta(TM) for Multiple Sclerosis Conference Call

PR Newswire September 11, 2014

Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day

PR Newswire September 10, 2014

Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program

PR Newswire September 8, 2014

Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC

PR Newswire September 7, 2014

Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City

PR Newswire September 3, 2014